person · Reporting owner

MOMTAZEE JAMES C

Disclosed activity across 5 companies

Tapewire entity: 29296
SEC CIK: 0001209181

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BridgeBio Pharma, Inc.BBIO · Entity 3360	Director	June 22, 2026	June 24, 2026
Roivant Sciences Ltd.ROIV · Entity 3185	Director	September 16, 2026	September 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BridgeBio Pharma, Inc.

Report date June 22, 2026 · Filed June 24, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	19,070	Reported balance After 2026-06-22 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-22 · Grant · Acquired 3,990 · Balance 19,070 F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3: The 80,000 shares reported herein as indirectly owned through the James C. Momtazee Revocable Trust (the "Trust") were previously reported as directly owned by the Reporting Person.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.92 · Expires 2036-06-21	Direct	5,277	Reported balance After 2026-06-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-22 · Grant · Acquired 5,277 · Balance 5,277 F4: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
Common StockSEC Table I · non-derivative	IndirectBy The James Momtazee Revocable Trust	80,000	Reported balance Holding disclosure · report date 2026-06-22 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 80,000 F3: The 80,000 shares reported herein as indirectly owned through the James C. Momtazee Revocable Trust (the "Trust") were previously reported as directly owned by the Reporting Person.

Filing footnotes · ownership attribution and instrument terms

F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F3: The 80,000 shares reported herein as indirectly owned through the James C. Momtazee Revocable Trust (the "Trust") were previously reported as directly owned by the Reporting Person.

F4: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

Roivant Sciences Ltd.

Report date September 16, 2026 · Filed September 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	111,959	Reported balance After 2026-09-16 transaction · row 1 1 source row Row 1 · 2026-09-16 · Grant · Acquired 5,054 · Balance 111,959 F1: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.57 · Expires 2036-09-15	Direct	10,531	Reported balance After 2026-09-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-09-16 · Grant · Acquired 10,531 · Balance 10,531 F2: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.

F2: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ENTELLUS MEDICAL INC

Report date February 28, 2018 · Filed March 01, 2018

Section 16 reporting ended · disclosed 2018-03-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.001 par valueSEC Table I · non-derivative	Direct	0	Reported balance After 2018-02-28 transaction · row 1 1 source row Row 1 · 2018-02-28 · Disposition to issuer · Disposed 3,750 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger, dated December 7, 2017, between Entellus Medical, Inc., Stryker Corporation and Explorer Merger Sub Corp. in exchange for a cash payment of $24.00 per share.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.67 · Expires 2027-07-14	Direct	0	Reported balance After 2018-02-28 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-02-28 · Disposition to issuer · Disposed 7,500 · Balance 0 F2: This option, which provided for vesting in 12 equal quarterly installments commencing on July 14, 2017, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to an Agreement and Plan of Merger, dated December 7, 2017, between Entellus Medical, Inc., Stryker Corporation and Explorer Merger Sub Corp. in exchange for a cash payment of $24.00 per share.

F2: This option, which provided for vesting in 12 equal quarterly installments commencing on July 14, 2017, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option.

Montes Archimedes Acquisition Corp

Report date September 30, 2021 · Filed October 04, 2021

Section 16 reporting ended · disclosed 2021-10-04. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

PRA Health Sciences, Inc.

Report date July 01, 2021 · Filed July 01, 2021

Section 16 reporting ended · disclosed 2021-07-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2021-07-01 transaction · row 1 1 source row Row 1 · 2021-07-01 · Disposition to issuer · Disposed 3,521 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (as it may be amended from time to time) (the "Merger Agreement"), dated as of February 24, 2021, by and among the Issuer, ICON plc ("ICON"), ICON US Holdings Inc. ("US HoldCo") and Indigo Merger Sub, Inc., each share of the Issuer's common stock was converted into the right to receive from ICON, 0.4125 of one ordinary share of ICON, and, from US HoldCo, $80.00 in cash, without any interest thereon (collectively, the "Merger Consideration"). F2: Pursuant to the Merger Agreement, each award of restricted stock of the Issuer that is outstanding immediately prior to the effective time of the merger was converted into the right to receive the Merger Consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (as it may be amended from time to time) (the "Merger Agreement"), dated as of February 24, 2021, by and among the Issuer, ICON plc ("ICON"), ICON US Holdings Inc. ("US HoldCo") and Indigo Merger Sub, Inc., each share of the Issuer's common stock was converted into the right to receive from ICON, 0.4125 of one ordinary share of ICON, and, from US HoldCo, $80.00 in cash, without any interest thereon (collectively, the "Merger Consideration").

F2: Pursuant to the Merger Agreement, each award of restricted stock of the Issuer that is outstanding immediately prior to the effective time of the merger was converted into the right to receive the Merger Consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 16, 2026 Filed Sep 18, 2026 23:01 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	GrantStock Option (Right to Buy) · Derivative	10,531	$0.00 Strike: $39.57	$0.00	Disclosure SEC source: 0001209181-26-000007 · wk-form4_1789772501.xml · derivative · entry 2 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,531 Underlying: Common Shares · 10,531 shares Expires 2036-09-15 F2 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. Read SEC document
September 16, 2026 Filed Sep 18, 2026 23:01 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	GrantCommon Shares	5,054	$0.00	$0.00	Disclosure SEC source: 0001209181-26-000007 · wk-form4_1789772501.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,959 F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. Read SEC document
September 10, 2026 Filed Sep 14, 2026 22:25 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	Tax withholdingCommon Shares	2,905	$40.94	$118,930.70	Disclosure SEC source: 0001209181-26-000005 · wk-form4_1789424742.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,905 F1 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. Read SEC document
July 17, 2026 Filed Jul 22, 2026 01:00 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	GrantCommon Shares	405	$0.00	$0.00	Disclosure SEC source: 0001140361-26-029193 · form4.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,810 F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document
June 22, 2026 Filed Jun 24, 2026 22:05 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantStock Option (Right to Buy) · Derivative	5,277	$0.00 Strike: $68.92	$0.00	Disclosure SEC source: 0001470831-26-000628 · wk-form4_1782338732.xml · derivative · entry 3 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,277 Underlying: Common Stock · 5,277 shares Expires 2036-06-21 F4 · derivative.exercise_date: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. Read SEC document
June 22, 2026 Filed Jun 24, 2026 22:05 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantCommon Stock	3,990	$0.00	$0.00	Disclosure SEC source: 0001470831-26-000628 · wk-form4_1782338732.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,070 F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · balance_after: The 80,000 shares reported herein as indirectly owned through the James C. Momtazee Revocable Trust (the "Trust") were previously reported as directly owned by the Reporting Person. Read SEC document
April 17, 2026 Filed Apr 21, 2026 22:32 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	Tax withholdingCommon Shares	94	$29.83	$2,804.02	Disclosure SEC source: 0001209181-26-000003 · wk-form4_1776810776.xml · nonDerivative · entry 2 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,405 F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. Read SEC document
April 17, 2026 Filed Apr 21, 2026 22:32 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	GrantCommon Shares	469	$0.00	$0.00	Disclosure SEC source: 0001209181-26-000003 · wk-form4_1776810776.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,499 F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document
January 20, 2026 Filed Jan 23, 2026 02:00 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	Tax withholdingCommon Shares	122	$22.98	$2,803.56	Disclosure SEC source: 0001140361-26-002087 · form4.xml · nonDerivative · entry 2 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,030 F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. Read SEC document
January 20, 2026 Filed Jan 23, 2026 02:00 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	GrantCommon Shares	609	$0.00	$0.00	Disclosure SEC source: 0001140361-26-002087 · form4.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,152 F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document
October 20, 2025 Filed Oct 23, 2025 01:01 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	Tax withholdingCommon Shares	158	$17.74	$2,802.92	Disclosure SEC source: 0001140361-25-038996 · form4.xml · nonDerivative · entry 2 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,543 F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. Read SEC document
October 20, 2025 Filed Oct 23, 2025 01:01 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	GrantCommon Shares	789	$0.00	$0.00	Disclosure SEC source: 0001140361-25-038996 · form4.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,701 F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document
September 10, 2025 Filed Sep 13, 2025 01:00 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	GrantStock Option (Right to Buy) · Derivative	33,726	$0.00 Strike: $13.77	$0.00	Disclosure SEC source: 0001140361-25-034930 · form4.xml · derivative · entry 3 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,726 Underlying: Common Shares · 33,726 shares Expires 2035-09-09 F3 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date. Read SEC document
September 10, 2025 Filed Sep 13, 2025 01:00 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	OtherCommon Shares	3,282	$13.77	$45,193.14	Disclosure SEC source: 0001140361-25-034930 · form4.xml · nonDerivative · entry 2 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,912 F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. Read SEC document
September 10, 2025 Filed Sep 13, 2025 01:00 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	GrantCommon Shares	14,524	$0.00	$0.00	Disclosure SEC source: 0001140361-25-034930 · form4.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,194 F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date. F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date. Read SEC document
July 17, 2025 Filed Jul 22, 2025 01:00 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	Tax withholdingCommon Shares	241	$11.65	$2,807.65	Disclosure SEC source: 0001140361-25-026648 · form4.xml · nonDerivative · entry 2 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,670 F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. Read SEC document
July 17, 2025 Filed Jul 22, 2025 01:00 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	GrantCommon Shares	1,201	$0.00	$0.00	Disclosure SEC source: 0001140361-25-026648 · form4.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,911 F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document
June 20, 2025 Filed Jun 24, 2025 22:57 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantStock Option (Right to Buy) · Derivative	8,425	$0.00 Strike: $41.73	$0.00	Disclosure SEC source: 0000950170-25-089652 · ownership.xml · derivative · entry 2 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,425 Underlying: Common Stock · 8,425 shares Expires 2035-06-19 F3 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document
June 20, 2025 Filed Jun 24, 2025 22:57 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantCommon Stock	6,589	$0.00	$0.00	Disclosure SEC source: 0000950170-25-089652 · ownership.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,080 F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
April 17, 2025 Filed Apr 22, 2025 01:00 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	Tax withholdingCommon Shares	276	$10.15	$2,801.40	Disclosure SEC source: 0001140361-25-014801 · form4.xml · nonDerivative · entry 2 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,710 F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. Read SEC document
April 17, 2025 Filed Apr 22, 2025 01:00 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	GrantCommon Shares	1,379	$0.00	$0.00	Disclosure SEC source: 0001140361-25-014801 · form4.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,986 F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document
January 23, 2025 Filed Jan 28, 2025 02:00 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	Tax withholdingCommon Shares	306	$11.21	$3,430.26	Disclosure SEC source: 0001140361-25-002101 · form4.xml · nonDerivative · entry 2 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,607 F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. Read SEC document
January 23, 2025 Filed Jan 28, 2025 02:00 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	GrantCommon Shares	1,248	$0.00	$0.00	Disclosure SEC source: 0001140361-25-002101 · form4.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,913 F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document
October 21, 2024 Filed Oct 24, 2024 01:00 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	GrantCommon Shares	1,231	$0.00	$0.00	Disclosure SEC source: 0001140361-24-044061 · form4.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,665 F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document
September 12, 2024 Filed Sep 17, 2024 01:00 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	OtherCommon Shares	3,056	$12.12	$37,038.72	Disclosure SEC source: 0001140361-24-041232 · form4.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,434 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document
September 10, 2024 Filed Sep 13, 2024 01:00 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	GrantStock Option (Right to Buy) · Derivative	27,894	$0.00 Strike: $12.19	$0.00	Disclosure SEC source: 0001140361-24-040984 · form4.xml · derivative · entry 2 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,894 Underlying: Common Shares · 27,894 shares Expires 2034-09-09 F2 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date. Read SEC document
September 10, 2024 Filed Sep 13, 2024 01:00 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	GrantCommon Shares	16,406	$0.00	$0.00	Disclosure SEC source: 0001140361-24-040984 · form4.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,490 F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date. F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date. Read SEC document
July 23, 2024 Filed Jul 26, 2024 01:00 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	GrantCommon Shares	1,555	$0.00	$0.00	Disclosure SEC source: 0001140361-24-034280 · form4.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,091 F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document
June 21, 2024 Filed Jun 25, 2024 21:39 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantStock Option (Right to Buy) · Derivative	26,014	$0.00 Strike: $27.36	$0.00	Disclosure SEC source: 0000950170-24-077448 · ownership.xml · derivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,014 Underlying: Common Stock · 26,014 shares Expires 2034-06-20 F1 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 21, 2024, such that all of the underlying shares will be vested on June 21, 2027, subject to the Reporting Person's continued service on the board of directors of the Issuer. Read SEC document
April 24, 2024 Filed Apr 27, 2024 01:01 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	Tax withholdingCommon Shares	293	$10.90	$3,193.70	Disclosure SEC source: 0001140361-24-022619 · form4.xml · nonDerivative · entry 2 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,536 F3 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. F2 · balance_after: The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein and the filing of this statement shall not be deemed an admission that the reporting person is, for purposes of Section 16 or otherwise, the beneficial owner of any of the reported securities. Read SEC document
April 24, 2024 Filed Apr 27, 2024 01:01 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	GrantCommon Shares	1,490	$0.00	$0.00	Disclosure SEC source: 0001140361-24-022619 · form4.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,829 F1 · shares: Reflects an award of restricted stock covering Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F2 · balance_after: The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein and the filing of this statement shall not be deemed an admission that the reporting person is, for purposes of Section 16 or otherwise, the beneficial owner of any of the reported securities. Read SEC document
January 19, 2024 Filed Jan 24, 2024 02:00 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	GrantCommon Shares	1,570	$0.00	$0.00	Disclosure SEC source: 0001140361-24-003554 · form4.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,339 F1 · shares: Reflects an award of restricted stock covering Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F2 · balance_after: The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein and the filing of this statement shall not be deemed an admission that the reporting person is, for purposes of Section 16 or otherwise, the beneficial owner of any of the reported securities. Read SEC document
October 17, 2023 Filed Oct 19, 2023 01:30 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	OtherCommon Shares	687	$10.30	$7,076.10	Disclosure SEC source: 0001140361-23-048777 · form4.xml · nonDerivative · entry 2 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,769 F3 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the above award of restricted stock covering Common Shares. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · balance_after: The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein and the filing of this statement shall not be deemed an admission that the reporting person is, for purposes of Section 16 or otherwise, the beneficial owner of any of the reported securities. Read SEC document
September 18, 2023 Filed Sep 21, 2023 01:33 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	OtherCommon Shares	6,752	$11.17	$75,419.84	Disclosure SEC source: 0001140361-23-044653 · form4.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,862 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4 Read SEC document
September 12, 2023 Filed Sep 15, 2023 01:31 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	GrantStock Option (Right to Buy) · Derivative	26,595	$0.00 Strike: $11.22	$0.00	Disclosure SEC source: 0001140361-23-044043 · form4.xml · derivative · entry 2 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,595 Underlying: Common Shares · 26,595 shares Expires 2033-09-11 F2 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date. Read SEC document
September 12, 2023 Filed Sep 15, 2023 01:31 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	GrantCommon Shares	17,825	$0.00	$0.00	Disclosure SEC source: 0001140361-23-044043 · form4.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,614 F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date. F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date. Read SEC document
July 03, 2023 Filed Jul 7, 2023 01:30 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	GrantCommon Shares	1,664	$0.00	$0.00	Disclosure SEC source: 0001140361-23-033548 · form4.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,789 F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document
June 21, 2023 Filed Jun 23, 2023 20:22 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantStock Option (right to buy) · Derivative	51,501	$0.00 Strike: $16.75	$0.00	Disclosure SEC source: 0001209191-23-039387 · doc4.xml · derivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,501 Underlying: Common Stock · 51,501 shares Expires 2033-06-21 F1 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document
April 03, 2023 Filed Apr 6, 2023 01:31 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	GrantCommon Shares	1,351	$0.00	$0.00	Disclosure SEC source: 0001140361-23-016868 · form4.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,125 F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document
January 03, 2023 Filed Jan 6, 2023 02:30 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	GrantCommon Shares	2,447	$0.00	$0.00	Disclosure SEC source: 0001140361-23-000728 · form4.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,774 F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document
October 31, 2022 Filed Nov 2, 2022 21:57 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	GrantCommon Shares	3,404	$0.00	$0.00	Disclosure SEC source: 0001140361-22-039660 · form4.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,327 F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document
October 16, 2022 Filed Oct 19, 2023 01:30 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	GrantCommon Shares	1,594	$0.00	$0.00	Disclosure SEC source: 0001140361-23-048777 · form4.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,456 F1 · shares: Reflects an award of restricted stock covering Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F2 · balance_after: The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein and the filing of this statement shall not be deemed an admission that the reporting person is, for purposes of Section 16 or otherwise, the beneficial owner of any of the reported securities. Read SEC document
September 15, 2022 Filed Sep 20, 2022 01:53 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	GrantStock Option (Right to Buy) · Derivative	68,897	$0.00 Strike: $3.50	$0.00	Disclosure SEC source: 0001140361-22-033878 · form4.xml · derivative · entry 2 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,897 Underlying: Common Shares · 68,897 shares Expires 2032-09-14 F2 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 15, 2023, subject generally to the reporting person's continuous service through such date. Read SEC document
September 15, 2022 Filed Sep 20, 2022 01:53 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	GrantCommon Shares	50,000	$0.00	$0.00	Disclosure SEC source: 0001140361-22-033878 · form4.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,923 F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 15, 2023, subject generally to the reporting person's continuous service through such date. F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 15, 2023, subject generally to the reporting person's continuous service through such date. Read SEC document
July 20, 2022 Filed Jul 25, 2022 10:06 UTC	Roivant Sciences Ltd. ROIV · Entity 3185	GrantCommon Shares	3,923	$0.00	$0.00	Disclosure SEC source: 0000899243-22-026616 · doc4.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,923 F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document
June 22, 2022 Filed Jun 24, 2022 20:32 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantStock Option (right to buy) · Derivative	104,921	$0.00 Strike: $8.45	$0.00	Disclosure SEC source: 0001209191-22-039259 · doc4.xml · derivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,921 Underlying: Common Stock · 104,921 shares Expires 2032-06-22 F1 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document
December 29, 2021 Filed Jan 4, 2022 00:47 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	PurchaseCommon Stock	80,000	$14.50	$1,160,000.00	Disclosure SEC source: 0000899243-22-000174 · doc4.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,491 Read SEC document
July 01, 2021 Filed Jul 1, 2021 21:36 UTC	PRA Health Sciences, Inc. PRAH · Entity 15912	Disposition to issuerCommon Stock	3,521	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-21-088352 · tm2121280-4_4seq1.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger (as it may be amended from time to time) (the "Merger Agreement"), dated as of February 24, 2021, by and among the Issuer, ICON plc ("ICON"), ICON US Holdings Inc. ("US HoldCo") and Indigo Merger Sub, Inc., each share of the Issuer's common stock was converted into the right to receive from ICON, 0.4125 of one ordinary share of ICON, and, from US HoldCo, $80.00 in cash, without any interest thereon (collectively, the "Merger Consideration"). F2 · price: Pursuant to the Merger Agreement, each award of restricted stock of the Issuer that is outstanding immediately prior to the effective time of the merger was converted into the right to receive the Merger Consideration. Read SEC document
June 17, 2021 Filed Jun 22, 2021 23:21 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantStock Option (right to buy) · Derivative	38,895	$0.00 Strike: $62.63	$0.00	Disclosure SEC source: 0000899243-21-025402 · doc4.xml · derivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,895 Underlying: Common Stock · 38,895 shares Expires 2031-06-16 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in three annual installments after June 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date. Read SEC document
June 01, 2021 Filed Jun 3, 2021 20:04 UTC	PRA Health Sciences, Inc. PRAH · Entity 15912	GrantCommon Stock	330	$0.00	$0.00	Disclosure SEC source: 0001104659-21-076355 · tm2118302-6_4seq1.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,521 F1 · kind: Represents a grant of restricted stock granted under the PRA Health Sciences, Inc. 2020 Stock Incentive Plan that will vest on June 1, 2022, subject to continued service on such date. Further, the grant shall vest in full upon a change in control as defined under the applicable award agreement. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.